NCT04053621 - Co-administration of Thiamine Pyrophosphate and Metformin in Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2021

Primary Completion Date

January 31, 2022

Study Completion Date

March 31, 2022

Conditions

Diabetes Mellitus, Type 2

Interventions

DIETARY_SUPPLEMENT

Thiamine pyrophosphate

12 weeks of weekly dose of 1 gram of thiamine pyrophosphate administered in an intravenous manner with saline solution

OTHER

Placebo

12 weeks of weekly dose of 275 ml of saline solution administered in an intravenous manner

DRUG

Metformin

All participants will continue taking metformin in their previous established tolerated dose for the duration of the study

Trial Locations (1)

Centro Especializado en Diabetes, Obesidad, Prevención y Enfermedades Cardiovasculares, S.C., Mexico City